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Abstract
Aims: Conflicting data exist on the impact on outcome of the use of different stent types during carotid 
artery stenting (CAS). The aim of this study was to evaluate clinical outcomes according to different carotid 
stent design among the population of the European Registry of Carotid Artery Stenting (ERCAS).
Methods and results: The present study was conducted in 1,604 patients who underwent neuroprotected 
CAS in ERCAS. All types of commercially available carotid stent were used. Open-cell design stents were 
classified according to free cell area into <7.5 mm2 or >7.5 mm2. A total of 713 closed-cell, 456 hybrid-cell, 
238 <7.5 mm2 open-cell, and 197 >7.5 mm2 open-cell stents were implanted. Overall, the 30-day stroke and 
death rate was 1.37%. At 30 days, 19 strokes occurred (1.18%): eight in the group of patients treated with 
a closed-cell (1.12%), two in those with a hybrid-cell (0.44%), three in those with a <7.5 mm2 open-cell 
(1.26%), and six in those treated with a >7.5 mm2 open-cell stent (3.05%) (p=0.045).
Conclusions: Data of the present study suggest that, in the setting of neuroprotected CAS performed in 
high-volume centres by properly trained operators, the use of an open-cell design stent with a free cell area 
>7.5 mm2 may be associated with an increased 30-day stroke risk.
KEYWORDS
• carotid arteries
• stents
• stroke
SUBMITTED ON 24/05/2015 - REVISION RECEIVED ON 1st 17/10/2015 / 2nd 07/01/2016 - ACCEPTED ON 30/03/2016
e266
EuroIntervention 2
0
16
;1
2
:e
2
6
5
-e
2
70
Introduction
Carotid artery stenting (CAS) is considered a less invasive treatment 
alternative to carotid endarterectomy (CEA) to reduce the risk of 
stroke in patients with significant carotid artery stenosis1. Although 
some predictors of adverse outcomes after CAS have been iden-
tified, the effects of device characteristics, including stent design, 
on neurologic adverse events have not been established. Carotid 
stents of different structural designs are available. “Open cell” and 
closed cell” stent designs differ not only in how the stent struts are 
connected but also in terms of the range of free cell area between 
the metal scaffolding2. Recent observational retrospective studies 
suggest that the use of closed-cell stents may be associated with 
lower stroke and death rates after CAS compared with open-cell 
stents3,4. In particular, a large retrospective, non-randomised study 
showed that, especially in symptomatic patients, who are known to 
have emboligenic plaque, the choice of a stent with a small free cell 
area resulted in a significant decrease in post-procedural events3. 
However, a randomised trial demonstrated no difference in the 
occurrence of cerebral microembolisations, as detected by diffusion-
weighted magnetic resonance imaging (DW-MRI) and transcranial 
Doppler (TCD), when an open or a closed-cell design stent5 was 
used, but unfortunately the study was underpowered to detect differ-
ence in clinical outcomes. Therefore, at present, little and conflict-
ing evidence exists on the impact on outcome of the use of different 
carotid stent types during neuroprotected CAS.
The aim of this study was to evaluate clinical outcomes accord-
ing to different carotid stent design among the patient population 
of the European Registry of Carotid Artery Stenting (ERCAS)6.
Methods
STUDY POPULATION
From January to December 2007, 1,611 patients underwent CAS 
at eight different institutions6. The 1,611 patients represent all 
the CAS procedures performed at the selected centres during the 
trial period. The selection criterion was the stenosis grade deter-
mined based on echo duplex and pre-interventional angiography7,8 
according to NASCET criteria:
1) Symptomatic stenosis of the internal carotid artery ≥50%, or
2) Asymptomatic stenosis ≥80% and estimated life expectancy of 
>5 years.
For the purposes of this study, “symptomatic” patients were 
defined as those with ipsilateral amaurosis fugax, ipsilateral hemi-
spheric TIA(s), or ipsilateral ischaemic stroke without major dis-
ability (Barthel ≤60, National Institutes of Health Stroke Scale 
[NIHSS] <15, Rankin >3) within six months before intervention. 
Patients were considered at high surgical risk if presenting with at 
least one or more high-risk criteria in either medical comorbidi-
ties (age >80 years; CCS angina class III-IV or unstable angina; 
congestive heart failure NYHA Class III-IV; left ventricular ejec-
tion fraction <30%; presence of left main stem or ≥ two coronary 
artery severe stenoses; need for urgent [<30 days] heart surgery; 
recent myocardial infarction [<30 days]; severe chronic lung dis-
ease; severe renal disease) or anatomical criteria (high cervical 
lesion; lesion below clavicle, prior radical neck surgery, or radi-
ation; CEA restenosis; contralateral carotid occlusion; tracheo-
stomy; contralateral laryngeal nerve palsy)2.
CONCOMITANT THERAPY
All patients received aspirin (75-160 mg/day), and should have 
been on ticlopidine (250 mg twice daily) or clopidogrel (75 mg 
once daily) for at least seven days. Alternatively, patients received 
clopidogrel preload (300 mg) 24 hrs before the procedure. After 
the stenting procedure, thienopyridines were continued for three 
months, whereas aspirin was continued for life. For anticoagula-
tion, 70-100 UI/kg of heparin was administered with the inten-
tion of achieving an ACT >250 s during the carotid intervention. 
Additional heparin was administered at the operator’s discretion.
CAS PROCEDURE
All procedures were performed percutaneously, with the patient 
under local anaesthesia. Each of the primary operators performing 
the procedures at each centre had to have fulfilled qualification 
for training and competence as described by the ICCS-SPREAD 
Joint Committee9, i.e., at least 150 procedures of supra-aortic 
vessel engagement (during diagnostic as well as interventional 
procedures) within two years, of which at least 100 were as the 
primary operator and at least 75 carotid stenting procedures, of 
which at least 50 were as the primary operator, within a two-
year fellowship. The minimum requirement to maintain techni-
cal skill (competence) is 50 carotid stenting procedures performed 
and documented by each primary operator per year. CAS was 
performed percutaneously and according to each unit’s existing 
standards of care. All commercially available embolic protection 
systems (EPS) could be used: distal EPS (distal filters and dis-
tal occlusion devices) and proximal EPS (endovascular occlusion 
and flow reversal). Dedicated self-expanding carotid stents were 
used: nitinol stents (either closed, open or hybrid cell design) and 
stainless steel stents were used. Examples of strut design of dif-
ferent types of carotid stent are given in Figure 1. In each centre, 
an independent neurologist or NIHSS-certified operator evaluated 
all patients before the procedure and in case of any clinical event 
occurring during follow-up.
DEFINITIONS
The primary endpoint of the present study was 30-day survival 
free of any stroke. The secondary endpoint was 30-day survival 
free of death and any stroke. Neurological events were classified 
as one of the following: 1) minor stroke defined as a new neu-
rological deficit that either resolved completely within 30 days 
or increased the NIHSS by ≤3; 2) major stroke defined as a new 
neurological deficit that persisted for >30 days and increased the 
NIHSS by ≥48.
FOLLOW-UP
All patients were followed up at one month after CAS with a clinical 
examination and a structured questionnaire assessing overall general 
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Stent design affects post-CAS stroke rates 
conditions, with specific emphasis on neurological symptoms, medi-
cation, hospitalisations, or any type of complication post procedure.
AUDITING PROCESS
A clinical committee, including three physicians (a neurologist, 
a cardiologist, and a vascular surgeon) not having any finan-
cial relationship with any of the institutions involved in the reg-
istry, reviewed all the charts in which any of the clinical events 
occurred. All of the centres adopted the same worksheet con-
taining multiple entry fields for each treated patient. Ten patient 
charts were randomly selected in each centre and verified against 
the reported data. The level of discrepancy between reported data 
and charts was a measure of compliance. Typing errors were con-
sidered irrelevant. Lack of event reporting would have been con-
sidered a severe discrepancy leading to centre exclusion from the 
registry.
STATISTICAL ANALYSIS
Statistical analyses were performed using IBM SPSS Statistics 
for Windows, Version 21.0 (IBM Corp., Armonk, NY, USA). 
Continuous variables were reported as mean±standard deviation. 
Other variables were expressed as absolute numbers and per-
centage. Comparisons were made by one-way ANOVA or χ2 test 
as appropriate. All statistical tests were two-sided. For all tests, 
a p-value <0.05 was considered statistically significant.
Results
Demographic and procedure-related characteristics of the entire 
ERCAS registry study population (n=1,611) are reported else-
where6. No clinically relevant discrepancies between reported data 
and charts were detected during the audit process. From the origi-
nal registry population, seven patients were excluded (no events at 
follow-up), four because no embolic protection device was used, 
two because more than one stent was implanted, and one since 
no stent was implanted. Table 1 shows baseline clinical and pro-
cedure-related characteristics of the study population (n=1,604). 
Figure 1. Examples of strut design of different types of carotid stent. 
A) Closed-cell stent. B) Open-cell stent with free cell area <7.5 mm2. 
C) Hybrid stent. D) Open-cell stent with free cell area >7.5 mm2.
Table 1. Baseline and procedural characteristics of the study 
population (N=1,604).
Number
Percentage or 
mean (SD)
Age (years) 72.1 (8.4)
Age ≥80 years 309 19.3
Male gender 1,099 68.5
High surgical risk 499 31.1
Symptomatic CVD 439 27.4
Risk factors
Smoking history 805 50.2
Hypertension 1,198 74.7
Diabetes mellitus 559 34.9
LDL >100 mg/dl 1,033 64.4
Embolic protection device
Proximal 524 32.7
Distal 1,080 67.3
Stent design
Closed 713 44.5
Hybrid 456 28.4
Open with free cell area <7.5 mm2 238 14.8
Open with free cell area >7.5 mm2 197 12.3
CVD: cerebrovascular disease; LDL: low-density lipoprotein; 
SD: standard deviation
The population enrolled exhibited a robust prevalence of cardio-
vascular risk factors. Octogenarians were quite numerous (19.3% 
of the total group) and almost one third of the patients were at 
high risk for CEA. Almost one third of the patients were symp-
tomatic in the previous six months. Overall, 713 closed-cell, 456 
hybrid-cell, 238 <7.5 mm2 open-cell, and 197 >7.5 mm2 open-
cell stents were implanted. When comparing patient character-
istics among the four cohorts receiving different carotid stents 
there were significant differences in cardiovascular risk factors 
(Table 2). Furthermore, symptomatic patients were more likely to 
receive a closed-cell stent (Table 2).
Overall in-hospital mortality was 0.06% (one patient), whereas 
the in-hospital stroke incidence was 0.50% (eight patients). Of 
these, six were major strokes and two were minor strokes. During 
the 30-day follow-up, three deaths (0.19%) and 11 strokes (0.69%) 
occurred (only one stroke was fatal). Among the strokes, three 
were major and eight were minor. All strokes were clinically 
considered ipsilateral to the treated artery and no haemorrhagic 
strokes occurred. Cumulative 30-day mortality was 0.25% (four 
patients) and stroke incidence was 1.12% (19 patients). Outcomes 
at 30-day follow-up according to stent type are reported in Table 3. 
No difference was observed among the groups for mortality and 
cumulative death and stroke incidence, whereas there was a signif-
icant difference in stroke incidence, with the lowest incidence in 
patients treated with a hybrid stent and the highest in those treated 
with an open stent with free cell area >7.5 mm2 (Table 3).
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Discussion
The results of this registry suggest that the use of an open-cell 
design stent with a free cell area >7.5 mm2 may be associated with 
an increased 30-day stroke risk. The 30-day stroke/death rate in 
the present registry is comparable to other prospective, multicen-
tre, controlled trials, or registries evaluating CAS in high-volume 
centres. Similar to other trials and registries, this registry6 con-
firmed a negative effect of age and of high surgical risk status on 
CAS outcomes10-12.
Conflicting evidence exists on the impact of the use of dif-
ferent carotid stent types on post-procedural neurologic adverse 
events. Observational retrospective studies suggest that the use 
of closed-cell stents was associated with reduced stroke and 
death rates after CAS compared with open-cell stents3,4. This 
effect was particularly evident in the treatment of symptomatic 
patients, who are known to have friable plaque, and the choice 
of a stent with a small free cell area has been shown to be asso-
ciated with a significant decrease in post-procedural events3. On 
the other hand, another retrospective study conducted in 194 
patients13 showed that an open-cell stent design was related to 
fewer cerebral ischaemic lesions following CAS without EPD. 
Moreover, another large retrospective study14, including a large 
consecutive number of patients (n=1,684) from 10 European 
centres, failed to identify any impact of stent design on patients’ 
clinical outcome, in either the early or the late post-procedure 
period. This was evident for both symptomatic (n=674) and 
asymptomatic (n=1,010) patients. Only one small randomised 
trial demonstrated no difference in the occurrence of cerebral 
microembolisation with closed-cell and open-cell stents in the 
setting of neuroprotected CAS, but unfortunately the study was 
underpowered to detect difference in clinical outcomes5. In line 
with these results, a large study evaluating the impact of open vs. 
closed-cell stent design (a registry involving 4,337 CAS patients 
treated with and without EPD) demonstrated that in-hospital and 
30-day death/stroke/myocardial infarction rates were not signifi-
cantly influenced by stent cell design15.
Operator experience is a well-recognised determinant of post-
procedural outcomes12,16,17 and its variability may explain, at least 
in part, the conflicting findings observed in the above-mentioned 
studies3-5,13-15. In the ERCAS registry6, all of the operators ful-
filled specific and complex criteria of training and clinical com-
petence. This could have eliminated the confounding effect of 
operator experience on procedural outcomes and allowed us to 
investigate better the role of patient and procedural character-
istics. Other issues may be involved in the conflicting results 
emerging from studies conducted up until now. First of all, the 
excellent results with both open and closed-cell stents may not 
have had enough power to detect a clinical difference between 
the groups studied. Also, the timing of adverse events could have 
influenced the different results observed in the literature. Indeed, 
from a technical point of view, the closed-cell stents may con-
fer benefits in later follow-up while open stents may be more 
easily advanced through difficult anatomies, affecting in-hospital 
events.
Table 3. Outcomes according to different types of stent at 30-day follow-up.
Closed
(n=713)
Hybrid
(n=456)
Open with free cell area 
<7.5 mm2 (n=238)
Open with free cell area 
>7.5 mm2 (n=197)
p-value
Death, n (%) 1 (0.14) 3 (0.66) 0 0 0.213
Stroke, n (%) 8 (1.12) 2 (0.44) 3 (1.26) 6 (3.05) 0.045
Death and stroke, n (%) 8 (1.12) 5 (1.10) 3 (1.26) 6 (3.05) 0.196
Table 2. Baseline characteristics according to different types of carotid stent.
Closed  
(n=713)
Hybrid  
(n=456)
Open with free cell area 
<7.5 mm2 (n=238)
Open with free cell area 
>7.5 mm2 (n=197)
p-value
Age 72.3±8.7 71.6±8.5 72.1±7.8 72.8±8.0 0.348
Age ≥80 years, n (%) 151 (21.2) 84 (18.4) 33 (13.9) 41 (20.8) 0.084
Male gender, n (%) 496 (69.6) 311 (68.2) 160 (67.2) 132 (67.0) 0.855
High surgical risk, n (%) 233 (32.7) 123 (27.0) 77 (32.4) 66 (33.5) 0.161
Symptomatic CVD, n (%) 240 (33.7) 87 (19.1) 67 (28.1) 45 (22.8) 0.001
Risk factors
Smoking history, n (%) 337 (47.3) 276 (60.5) 130 (54.6) 62 (31.5) 0.001
Hypertension, n (%) 453 (63.5) 399 (87.5) 190 (79.8) 156 (79.2) 0.001
Diabetes mellitus, n (%) 269 (37.7) 136 (29.8) 80 (33.6) 74 (37.6) 0.037
LDL >100 mg/dl, n (%) 429 (60.2) 319 (69.9) 157 (66.0) 128 (65.0) 0.007
CVD: cerebrovascular disease; LDL: low-density lipoprotein
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Stent design affects post-CAS stroke rates 
The present study suggests that, in the setting of neuropro-
tected CAS performed in high-volume centres by properly trained 
operators, stent design may affect procedural outcomes. All com-
mercially available carotid stents are able to contain the carotid 
plaque and avoid the possibility of post-procedural embolisation. 
However, in the present study, the use of stents with a large free 
cell area (>7.5 mm2) was associated with a higher risk of post-
procedural strokes, probably because of a lower ability to contain 
the friable atherosclerotic plaque. This could protrude through the 
stent mesh and possibly embolise distally in the days following the 
endovascular procedure. In this regard, recent studies using high-
resolution imaging modalities such as optical coherence tomogra-
phy post CAS have shown that plaque prolapse was significantly 
more frequent in open-cell carotid stents compared to closed-cell 
design stents18,19.
Study limitations
Although this study involved a large cohort of CAS patients 
(>1,600), it is a retrospective non-randomised analysis, and the 
relatively small number of events makes it underpowered to come 
to definitive conclusions. However, it has to be acknowledged that 
the excellent results associated with neuroprotected CAS may not 
easily allow powerful differences to be found between subgroups 
in real-world settings.
Because patients were not randomised to receive different types 
of carotid stent and the physician decided at his/her discretion 
which stent should be used, a selection bias could have occurred. 
Indeed, in the present study, symptomatic patients were more 
likely to receive closed-cell design stents compared to asympto-
matic ones. However, the fact that closed-cell stents were more 
likely to be used in patients at higher stroke risk (i.e., symptomatic 
patients) would, at least theoretically, have produced worse out-
comes in the closed-cell stent group. Therefore, although affected 
by selection bias, the findings of the present study are strongly 
suggestive of a worse outcome with open-cell design stents with 
a free cell area >7.5 mm2. Furthermore, it is important to consider 
that in this registry a post-discharge neurologist’s evaluation was 
carried out only if a “clinical event occurred”. This is a poten-
tial weakness as it could have led to under-reporting of neurologic 
events. However, such a methodology is largely used in regis-
tries reporting CAS and CEA outcomes12. Moreover, it should be 
considered that these results are not representative of all-comer 
patients but, in most of the enrolling centres, operators selected 
upfront which patients would be suitable for CAS and which for 
CEA.
Conclusions
Data of the present study suggest that, in the setting of neuropro-
tected CAS performed in high-volume centres by properly trained 
operators, the use of an open-cell design stent with a free cell area 
>7.5 mm2 may be associated with an increased 30-day stroke risk. 
Future randomised and, given the low event rates, larger popu-
lation trials would ideally be needed to confirm these findings.
Impact on daily practice
At present, little and conflicting evidence exists on the impact 
on outcome of the use of different carotid stent types during 
neuroprotected CAS. Data coming from the ERCAS registry 
suggest that, in the setting of neuroprotected CAS performed 
in high-volume centres by properly trained operators, the use 
of an open-cell design stent with a free cell area >7.5 mm2 may 
be associated with an increased 30-day stroke risk. Even if 
these findings need to be confirmed in larger, randomised trials, 
CAS operators should take into account that differences in stent 
design may affect outcome.
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